Cantor Fitzgerald upgrades Omeros stock rating on Yartemlea launch

Cantor Fitzgerald has raised its rating on Omeros stock following the successful launch of Yartemlea, a newly approved drug. The investment firm upgraded Omeros Corp. (NASDAQ:OMER) from a Neutral rating to Overweight and set a price target of $22.00 per share. Omeros' stock is currently trading at $18.49, close to its 52-week high of $19.65.

The firm's upgrade is based on stronger-than-expected performance following the drug's launch and positive feedback from physicians. The assessment was made after reviewing the company's second-quarter results, which also surpassed Wall Street expectations. Omeros reported adjusted earnings of $0.02 per share, a significant improvement from the prior year's $0.25 loss per share.

Revenue also exceeded forecasts, reaching $28.5 million compared to the expected $12.67 million. Omeros specializes in developing and commercializing pharmaceutical products and is based in Seattle.